Last update: Oct. 20, 2016


Low Risk for breastfeeding

Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Steroidal drug with glucocorticoid action and high activity as mineralocorticoid.
Systemic administration: oral route. Topical administration: creams as dermatologic compounds and eye drops for ophthalmologic use.
Indicated as replacement therapy in Adrenal Insufficiency (Addison’s Disease) and "salt-losing" Congenital Adrenal Hyperplasia.

At latest update relevant published data were not found on excretion into breast milk.
Other corticosteroids are know to be excreted into breastmilk in small amounts.
Since the goal of treatment is to keep the mother within normal plasma hormone ranges, by monitoring adequately through analytical controls to make sure the mother is receiving a correct dose, it would neither interfere with breastfeeding nor would be harmful to the infant. Take as lowest effective dose as possible with follow-up the infant for hypo-adrenal signs.

The small dose used along with a poor passage to plasma of most ophthalmologic and topical dermatologic preparations makes it very unlikely that a significant excretion into breastmilk would occur.
Do not apply on the breast to prevent ingestion by the infant; otherwise, do it just after a meal and clean the nipple thoroughly with water before the next feed. Mineral-corticoid poisoning occurred in an infant after long-term application of a corticoid cream on the nipple (De Stefano 1983).


We do not have alternatives for フルドロコルチゾン酢酸エステル.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

フルドロコルチゾン酢酸エステル is Fludrocortisone Acetate in Japanese.

Is written in other languages:

フルドロコルチゾン酢酸エステル is also known as


フルドロコルチゾン酢酸エステル belongs to these groups or families:


Main tradenames from several countries containing フルドロコルチゾン酢酸エステル in its composition:


Variable Value Unit
Oral Bioavail. 93 %
Molecular weight 423 daltons
Protein Binding 70 - 80 %
VD 1,1 l/Kg
Tmax 0,5 - 1,7 hours
T1/2 3,5 hours


  1. Polito A, Hamitouche N, Ribot M, Polito A, Laviolle B, Bellissant E, Annane D, Alvarez JC. Pharmacokinetics of oral fludrocortisone in septic shock. Br J Clin Pharmacol. 2016 Abstract
  2. AEMPS. Fludrocortisona. Ficha técnica. 2016 Full text (in our servers)
  3. ASPEN. Fludrocortisone. Drug Summary. 2015 Full text (in our servers)
  4. Merck Fludrocortison. Drogen Zusammenfassung. 2014 Full text (in our servers)
  5. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Full text (link to original source) Full text (in our servers)
  6. De Stefano P, Bongo IG, Borgna-Pignatti C, Severi F. Factitious hypertension with mineralocorticoid excess in an infant. Helv Paediatr Acta. 1983 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2021 from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM